Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia

2009 ◽  
pp. n/a-n/a ◽  
Author(s):  
Mehdi Hamadani ◽  
Farrukh T. Awan
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Novel Agents ◽  
Remission Induction ◽  
Acute Myeloid

scholarly journals Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

2014 ◽  
Vol 168 (1) ◽  
pp. 94-101 ◽  
Author(s):  
Seth E. Karol ◽  
Elaine Coustan-Smith ◽  
Xueyuan Cao ◽  
Sheila A. Shurtleff ◽  
Susana C. Raimondi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Therapy ◽  
Remission Induction ◽  
Excellent Response ◽  
Acute Myeloid

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

1987 ◽  
Vol 66 (1) ◽  
pp. 37-44 ◽  
Author(s):  
G. Tricot ◽  
M. A. Boogaerts ◽  
R. Vlietinck ◽  
M. P. Emonds ◽  
R. L. Verwilghen
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Remission Induction ◽  
Consolidation Therapy ◽  
Acute Myeloid

Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients

1986 ◽  
Vol 64 (3) ◽  
pp. 435-453 ◽  
Author(s):  
D. M. Swirsky ◽  
M. de Bastos ◽  
S. E. Parish ◽  
J. K. H. Rees ◽  
F. G. J. Hayhoe
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Adult Patients ◽  
Remission Induction ◽  
Acute Myeloid

Comparison of Different Chemotherapy Regimens in the Management of Acute Myeloid Leukaemia - 5 Years Experience from Pakistan.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4349-4349
Author(s):  
Khalil Ullah ◽  
Parvez Ahmed ◽  
Shahid Raza ◽  
Tariq Mahmood ◽  
Badshah Khan
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Armed Forces ◽  
Marrow Transplant ◽  
Remission Induction ◽  
All Trans Retinoic Acid ◽  
Group I ◽  
Group Ii ◽  
Acute Myeloid

Abstract OBJECTIVES: This is a retrospective study in acute myeloid leukaemia (AML) patients carried out at Armed Forces Bone Marrow Transplant Centre Rawalpindi Pakistan between July 2001 and June 2006. Aim of the study was to evaluate outcome in AML patients treated with different remission induction and consolidation chemotherapy regimens in our population. METHODS: During 5 years period between July 2001 to June 2006, 46 patients received treatment for AML at our centre. Twenty nine patients were males and 17 were females. Median age of patients was 21 years (range: 7–56 years). These 46 patients were categorized into two groups on the basis of type of leukaemia and chemotherapy given. In group-I 40 patients (group Ia: 23 patients of M1–M6, less M3 group Ib: 17 patients of AML M3) received anthracycline and cytarabin based chemotherapy. In group- II, six patients (AML- M3) received all trans retinoic acid (ATRA) based chemotherapy. RESULTS: In group Ia, out of 23 patients, 14 patients (60.8%) achieved complete remission (CR) after remission induction chemotherapy,10 patients remained in CR after 3rd and 4th consolidation. Eleven patients died and five patients relapsed during treatment and follow up. In this group overall CR, relapse rate (RR) and mortality was 30.4% (7/23), 21.7% (5/23) & 48% (11/23) respectively. In group Ib out of 17 patients, 9 patients (53%) achieved CR after remission induction. Eleven patients died during treatment while one patient relapsed in this group. Overall CR, RR & mortality was 29.4% (5/17), 6% (1/17) & 55% (11/17) respectively. In group II all patients achieved CR (100%) after 1st course of chemotherapy. Two of these patients unfortunately died of uncontrolled sepsis during 1st consolidation, while remaining 4 patients 66.6% are on maintenance chemotherapy and are still in CR. CONCLUSION: Overall CR, RR and mortality in all groups was 35% (16/46), 13% (6/46) and 52% (24/46) respectively at a median follow-up of 36 ± 8 months. Survival in AML-M3 patients treated with ATRA based chemotherapy is significantly superior than anthracycline based chemotherapy (66.6% vs 29.4%). Infection and chemotherapy toxicity being major causes of mortality.

Sign in / Sign up

Export Citation Format

Share Document